Mercado de anticuerpos de próxima generación: mapeo competitivo y perspectivas estratégicas para 2031

  • Report Code : TIPRE00006412
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 181
Buy Now

Se espera que el mercado de anticuerpos de próxima generación alcance los 12.050,13 millones de dólares en 2028, frente a los 5.468,41 millones de dólares de 2021; se estima que crecerá a una tasa compuesta anual del 11,9 % entre 2021 y 2028.

Los anticuerpos de próxima generación están diseñados para ser más específicos y, a menudo, más potentes que los anticuerpos monoclonales tradicionales. . Se requieren estrategias de anticuerpos de próxima generación para diseñar una terapia útil que combine anticuerpos, carga útil, enlazador y método de conjugación, garantizando al mismo tiempo la estabilidad, la administración dirigida y efectos limitados fuera del objetivo.

< p>El informe ofrece información y un análisis en profundidad del mercado de anticuerpos de próxima generación, enfatizando varios parámetros como tendencias del mercado, avances tecnológicos, dinámica del mercado y análisis del panorama competitivo de los principales actores del mercado en todo el mundo. También incluye el impacto de la pandemia de COVID-19 en el mercado en todas las regiones. La pandemia ha alterado las condiciones socioeconómicas de varios países del mundo. Actualmente, Estados Unidos es el país más afectado del mundo debido al brote de COVID-19 y tiene el mayor número de casos confirmados y muertes en todo el mundo, según las estadísticas recientes de la OMS. El elevado número de casos positivos de COVID-19 ha impactado negativamente a las economías globales. Ha habido una disminución en las actividades comerciales generales y el crecimiento de varias industrias que operan en todo el mundo.


Perspectivas estratégicas

El brote de COVID-19 ha supuesto una carga inmensa sobre infraestructura de atención médica en Estados Unidos, Canadá y México. Además, la mayoría de las empresas farmacéuticas y biotecnológicas y los institutos de investigación participan en el desarrollo de vacunas y medicamentos contra la COVID-19. Tanto las grandes empresas farmacéuticas como las pequeñas empresas emergentes se han presentado para promover tratamientos y vacunas dirigidos a la infección creada por el nuevo coronavirus. Como resultado, las actividades de investigación relacionadas con las vacunas en las empresas farmacéuticas y biotecnológicas, los centros de investigación y los institutos de investigación educativa se consideran esenciales y principalmente no se han visto afectadas en sus operaciones ni en su producción. Sin embargo, debido al aumento de las actividades de investigación, se prevé que crezca tanto la accesibilidad a la financiación para análisis como la necesidad de anticuerpos, incluidos los de próxima generación. Además, a raíz del brote de COVID-19, muchos investigadores de todo el mundo participan en el examen viral del SARS-CoV-2, el virus que desarrolla el COVID-19. Tanto para las vacunas como para las terapias, se examina la eficacia funcional de los anticuerpos generados para contrarrestar el virus objetivo. Por lo tanto, se espera que la pandemia de COVID-19 tenga un impacto positivo en el mercado de anticuerpos de próxima generación en los próximos años.

Según la región, el mercado de anticuerpos de próxima generación es segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y Asia. África y América del Sur y Central.

regiones lucrativas para el mercado de anticuerpos de próxima generación

 

Perspectivas del mercado

La creciente demanda de terapias con anticuerpos de próxima generación para impulsar el mercado de anticuerpos de próxima generación

Los crecientes desarrollos en biotecnología han llevado a una mayor aceptación de la próxima generación Terapéutica de anticuerpos, lo que está impulsando su uso en el tratamiento de enfermedades autoinmunes, inflamatorias y crónicas. Los tratamientos con anticuerpos de próxima generación han sido el resultado de la aplicación de tecnologías sofisticadas en la terapia con anticuerpos, como los conjugados anticuerpo-fármaco (ADC), anticuerpos modificados genéticamente y anticuerpos específicos (BsAb). Por lo tanto, se están estudiando ampliamente las aplicaciones de los anticuerpos de próxima generación para tratar diversas enfermedades crónicas como el cáncer, el VIH, enfermedades infecciosas, etc. La creciente demanda de estos anticuerpos ha resultado en un rápido aumento en la aprobación de ADC y otros anticuerpos de próxima generación. terapéutica. Por ejemplo, en mayo de 2020, Takeda Pharmaceutical Company Limited anunció la aprobación de la FDA de ALUNBRIG (brigatinib) para pacientes adultos con cáncer de pulmón de células no pequeñas (NSCLC) metastásico con linfoma anaplásico quinasa positivo (ALK+) detectado mediante una prueba aprobada por la FDA. . La indicación actual de ALUNBRIG se ha ampliado para abarcar el entorno de primera línea con su aprobación. ALUNBRIG es un inhibidor de la tirosina quinasa (TKI) de próxima generación diseñado para atacar las anomalías moleculares de ALK. De manera similar, en 2019, Genentech anunció la aprobación acelerada por la FDA de Polatuzumab vedotin-piiq, un conjugado de fármaco-anticuerpo dirigido a CD79b indicado en combinación con bendamustina y un producto de rituximab para pacientes adultos con linfoma difuso de células B grandes en recaída o refractario.

Por lo tanto, se prevé que el mercado de anticuerpos de próxima generación crezca rápidamente durante el período previsto debido al aumento de las aprobaciones de ensayos clínicos y la alta adopción de terapias con anticuerpos de próxima generación para el tratamiento de diversas enfermedades.

Perspectivas basadas en áreas terapéuticas

Basado en el área terapéutica, el mercado de anticuerpos de próxima generación se divide en oncología y autoinmune o inflamatorio. El segmento de oncología representó una mayor participación del mercado.  

Mercado de anticuerpos de próxima generación, por área terapéutica, 2021 y 2028

 

Información basada en tecnología

Basado en la tecnología, el mercado de anticuerpos de próxima generación se segmenta en conjugados anticuerpo-fármaco, anticuerpos biespecíficos, anticuerpos diseñados con Fc, fragmentos de anticuerpos y anticuerpos. proteínas similares a anticuerpos y productos de anticuerpos biosimilares. El segmento de conjugados anticuerpo-fármaco tuvo la mayor participación del mercado en 2021, y se estima que el mismo segmento registrará la CAGR más alta del 12,1% en el mercado durante el período de pronóstico.

 

Los actores del mercado de anticuerpos de próxima generación adoptan varias estrategias orgánicas, como el lanzamiento y la expansión de productos, para expandir su presencia y cartera de productos en todo el mundo y satisfacer la creciente demanda.

Perfiles de empresas

  • F. HOFFMANN-LA ROCHE LTD.  
  • Kyowa Kirin Co., Ltd.
  • Seagen Inc.                           
  • ImmunoGen, Inc. ;
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.                
  • Pfizer Inc.           
  • Catalent Inc        
  • AstraZeneca ;       
  • Xencor
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which is the potential market for next-generation antibodies in terms of the region?

The Asia Pacific registered as the fastest-growing region in the global next-generation antibody market. The market in this region is expected to grow significantly in countries such as China, Japan, and India. The market is driven by growing investments from international players in China and India, improving government support in countries such as China, expanding R&D, and advancing healthcare infrastructure. Therefore, the region holds huge potential for the next-generation antibody market players to grow during the forecast period.

What are the drivers and restraints for the next-generation antibody market?

The growth of the market is attributed to the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics drives the market growth. However, the complications associated with the manufacturing and approvals hampers the market growth.

Who are the key players in the next-generation antibody market?

The disposable pipettes tips market majorly consists of players like F. HOFFMANN-LA ROCHE LTD., Kyowa Kirin Co., Ltd., Seagen Inc., ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Pfizer Inc., Catalent Inc, AstraZeneca, and Xencor among others.

Which is the therapeutic area where the next-generation antibodies are often used?

The next-generation antibodies are used in the therapeutic areas- oncology and oncology, and autoimmune or inflammatory. Mostly, the next-generation antibodies are used in the oncology field. The oncology segment is likely to hold the largest share of the market in 2021. Moreover, the oncology segment is anticipated to register the highest CAGR in the market during the forecast period, due to the vast usage of next-generation antibodies for cancers, high volume consumption, and product innovation for this field

What is the market CAGR value of the next-generation antibody market during the forecast period?

The global next-generation antibody market is expected to reach US$ 5,428.41 million in 2028 from US$ 12,050.13 million in 2021. The market is estimated to grow with a CAGR of 11.9% from 2021-2028.

The List of Companies - Next-generation Antibody Market

  1. F. HOFFMANN-LA ROCHE LTD.      
  2. Kyowa Kirin Co., Ltd.         
  3. Seagen Inc.           
  4. ImmunoGen, Inc.              
  5. Takeda Pharmaceutical Company Limited               
  6. Amgen Inc.           
  7. Pfizer Inc.              
  8. Catalent Inc          
  9. AstraZeneca         
  10. Xencor

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports